36 related articles for article (PubMed ID: 16515631)
1. Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.
Mikuła-Pietrasik J; Witucka A; Pakuła M; Uruski P; Begier-Krasińska B; Niklas A; Tykarski A; Książek K
Cell Mol Life Sci; 2019 Feb; 76(4):681-697. PubMed ID: 30382284
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel-induced myocarditis presenting as new-onset heart failure.
Johnson D; Weisleder H; Yuan H; Carrozzi G
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38176758
[TBL] [Abstract][Full Text] [Related]
3. Model-based approach to identify predictors of paclitaxel-induced myelosuppression in "real-world" administration.
Salem AM; Dvergsten E; Karovic S; Maitland ML; Gopalakrishnan M
CPT Pharmacometrics Syst Pharmacol; 2023 Jul; 12(7):929-940. PubMed ID: 37101403
[TBL] [Abstract][Full Text] [Related]
4. Virtual Cancer Care During the COVID-19 Pandemic and Beyond: A Call for Evaluation.
Levine OH; McGillion M; Levine M
JMIR Cancer; 2020 Nov; 6(2):e24222. PubMed ID: 33180741
[TBL] [Abstract][Full Text] [Related]
5. Genitourinary disease risks among ovarian cancer survivors in a population-based cohort study.
Chang CP; Chen Y; Blackburn B; Abdelaziz S; Rowe K; Snyder J; Dodson M; Deshmukh V; Newman M; Stanford JB; Porucznik CA; Ose J; Fraser A; Smith K; Doherty J; Gaffney D; Hashibe M
Gynecol Oncol; 2020 May; 157(2):529-535. PubMed ID: 32122688
[TBL] [Abstract][Full Text] [Related]
6. Hearing loss and tinnitus in survivors with chemotherapy-induced neuropathy.
Miaskowski C; Paul SM; Mastick J; Schumacher M; Conley YP; Smoot B; Abrams G; Kober KM; Cheung S; Henderson-Sabes J; Chesney M; Mazor M; Wallhagen M; Levine JD
Eur J Oncol Nurs; 2018 Feb; 32():1-11. PubMed ID: 29353626
[TBL] [Abstract][Full Text] [Related]
7. Impact of chemotherapy-induced neurotoxicities on adult cancer survivors' symptom burden and quality of life.
Miaskowski C; Mastick J; Paul SM; Abrams G; Cheung S; Sabes JH; Kober KM; Schumacher M; Conley YP; Topp K; Smoot B; Mausisa G; Mazor M; Wallhagen M; Levine JD
J Cancer Surviv; 2018 Apr; 12(2):234-245. PubMed ID: 29159795
[TBL] [Abstract][Full Text] [Related]
8. Renal pelvic hemorrhage and acute renal failure associated with carboplatin therapy.
Krishnan SG; VanderBrink B; Weiss G; Singhal PC; Shah HH
Urology; 2007 Dec; 70(6):1222.e5-7. PubMed ID: 18158057
[TBL] [Abstract][Full Text] [Related]
9. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.
Marchetti C; De Felice F; Musella A; Palaia I; Monti M; Musio D; Muzii L; Tombolini V; Benedetti Panici P
Oncotarget; 2016 Sep; 7(36):58709-58715. PubMed ID: 27509061
[TBL] [Abstract][Full Text] [Related]
10. [Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].
Meerpohl HG
Praxis (Bern 1994); 1999 Mar; 88(12):513-8. PubMed ID: 10235026
[TBL] [Abstract][Full Text] [Related]
11. Devastating effects of chemotherapy: deafness and acute renal failure in a patient with epithelial ovarian cancer.
Ozguroglu M; Sari O; Turna H
Int J Gynecol Cancer; 2006; 16 Suppl 1():394-6. PubMed ID: 16515631
[TBL] [Abstract][Full Text] [Related]
12. Bilateral irreversible hearing loss associated with the combination of carboplatin and paclitaxel chemotherapy: a unusual side effect.
Salvinelli F; Casale M; Vincenzi B; Santini D; Di Peco V; Firrisi L; Onori N; Greco F; Tonini G
J Exp Clin Cancer Res; 2003 Mar; 22(1):155-8. PubMed ID: 12725337
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study.
Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma.
Abaid LN; Micha JP; Rettenmaier MA; Brown JV; Mendivil AA; Lopez KL; Goldstein BH
Cancer Chemother Pharmacol; 2013 Jul; 72(1):101-7. PubMed ID: 23660691
[TBL] [Abstract][Full Text] [Related]
15. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer.
Leiser AL; Maluf FC; Chi DS; Sabbatini P; Hensley ML; Schwartz L; Venkatraman E; Spriggs D; Aghajanian C
Int J Gynecol Cancer; 2007; 17(2):379-86. PubMed ID: 17362316
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
